Long-term Organ Damage Accrual and Safety in Patients with SLE Treated with Belimumab Plus Standard of Care
Lupus 2016;25:699–709
Both active disease and medication toxicity can result in the accrual of long-term organ damage in SLE.
In this analysis of pooled data from the BLISS-52 and BLISS-76 clinical trials, Bruce et al assess the mean change in SDI at Years 5–6 and the reported AEs over the entire study period in order to assess organ damage accrual during belimumab treatment. There was a low incidence of organ damage accrual and no unexpected AEs, even in the subgroup of patients at high risk of organ damage.